Investor Presentaiton

Providing a complete funding solution to MorphoSys Upfront cash payment Milestone payments Launch & Development Capital Equity purchase ~$1.4bn paid to MorphoSys on close(1) of Constellation Up to $150m of clinical, regulatory and commercial milestones Up to $350m with flexibility to draw over a one-year period with a minimum draw of $150m Up to ~$2 billion in funding ROYALTY PHARMA 1. Transaction closed on July 15, 2021; 1,337,552 ordinary shares of MorphoSys were acquired at a price of €63.35 per share on July 22, 2021. $100m Purchased at transaction close(1) 77

View entire presentation